Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiragolumab - Genentech

Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer

Most Recent Events

  • 26 Jun 2025 M. D. Anderson Cancer Center plans the phase II STRIVE trial for Lung cancer, Squamous cell cancer, and Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV), in December 2025 (NCT07038915)
  • 25 Apr 2025 Efficacy and adverse events data from a phase III SKYSCRAPER-01 trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 05 Mar 2025 Roche completes a phase II trial in Non-small cell lung cancer (Adjuvant therapy, Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA, Switzerland, Australia, Italy, Netherlands, Poland, South Korea, Spain (IV) (NCT04832854)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top